Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP7517 Monotherapy and With Pembrolizumab in Advanced Solid Tumors
NCT04837196Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- Nov 2021
- Primary completion
- Jun 2024
- Modality
- Prophylactic Vaccines, Gene Editing, Gene Silencing
- Countries
- 1
01
Overview
A Phase 2 trial of ASP7517 in solid tumor (advanced stage), melanoma, ovarian cancer, colorectal cancer (CRC), sponsored by Astellas Pharma. Started Nov 2021; status: completed.
02
Drugs
ASP7517
03
Conditions
solid tumor (advanced stage)melanomaovarian cancercolorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04837196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04837196.